Patients with KRAS mutant lung cancers frequently present with co-mutations in the KEAP1-NRF2 pathway, which results in the constitutive activation of the transcription factor NRF2 within the tumour cells [13]. This evidence concerns the gene NFE2L2 and neoplasm.